Ultragenyx (RARE) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
560.2M
Gross Profit
483.5M
86.30%
Operating Income
-536.0M
-95.67%
Net Income
-569.2M
-101.60%
EPS (Diluted)
-$6.29
Balance Sheet Metrics
Total Assets
1.5B
Total Liabilities
1.2B
Shareholders Equity
262.3M
Debt to Equity
4.73
Cash Flow Metrics
Operating Cash Flow
-414.4M
Free Cash Flow
-434.2M
Revenue & Profitability Trend
Ultragenyx Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 560.2M | 434.2M | 363.3M | 351.4M | 271.0M |
| Cost of Goods Sold | 76.7M | 45.2M | 28.3M | 16.0M | 6.1M |
| Gross Profit | 483.5M | 389.0M | 335.0M | 335.4M | 264.9M |
| Operating Expenses | 1.0B | 958.2M | 983.9M | 717.1M | 595.0M |
| Operating Income | -536.0M | -569.2M | -648.9M | -381.7M | -330.1M |
| Pre-tax Income | -567.6M | -608.5M | -701.7M | -453.0M | -185.4M |
| Income Tax | 1.6M | -1.8M | 5.7M | 1.0M | 1.2M |
| Net Income | -569.2M | -606.6M | -707.4M | -454.0M | -186.6M |
| EPS (Diluted) | -$6.29 | -$8.25 | -$10.12 | -$6.70 | -$3.07 |
Income Statement Trend
Ultragenyx Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 817.1M | 732.2M | 883.9M | 856.6M | 1.3B |
| Non-Current Assets | 686.3M | 758.8M | 661.5M | 665.8M | 464.3M |
| Total Assets | 1.5B | 1.5B | 1.5B | 1.5B | 1.8B |
| Liabilities | |||||
| Current Liabilities | 344.2M | 280.4M | 261.2M | 181.4M | 189.6M |
| Non-Current Liabilities | 897.0M | 935.2M | 931.7M | 418.5M | 415.6M |
| Total Liabilities | 1.2B | 1.2B | 1.2B | 599.8M | 605.2M |
| Equity | |||||
| Total Shareholders Equity | 262.3M | 275.4M | 352.5M | 922.6M | 1.2B |
Balance Sheet Composition
Ultragenyx Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -569.2M | -606.6M | -707.4M | -454.0M | -186.6M |
| Operating Cash Flow | -414.4M | -479.3M | -406.3M | -357.9M | 7.7M |
| Investing Activities | |||||
| Capital Expenditures | -7.5M | -44.3M | -116.1M | -73.1M | -43.9M |
| Investing Cash Flow | -5.3M | 170.5M | -261.7M | -195.4M | -179.1M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 388.0M | 379.7M | 490.4M | 78.5M | 511.0M |
| Free Cash Flow | -434.2M | -521.6M | -526.6M | -411.8M | -176.1M |
Cash Flow Trend
Ultragenyx Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-5.91
Forward P/E
-7.27
Price to Book
24.15
Price to Sales
5.95
PEG Ratio
-7.27
Profitability Ratios
Profit Margin
-93.04%
Operating Margin
-102.62%
Return on Equity
-377.06%
Return on Assets
-24.51%
Financial Health
Current Ratio
2.40
Debt to Equity
588.24
Beta
0.24
Per Share Data
EPS (TTM)
-$5.83
Book Value per Share
$1.54
Revenue per Share
$6.32
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| rare | 3.5B | -5.91 | 24.15 | -377.06% | -93.04% | 588.24 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.